| Title |
Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7
|
|---|---|
| Published in |
PharmacoEconomics, October 2012
|
| DOI | 10.2165/11587150-000000000-00000 |
| Pubmed ID | |
| Authors |
Frank R. Lichtenberg |
| Abstract |
This paper investigates the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. The effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany is examined, using longitudinal, annual, state-level data during the period 2001-7. The estimates imply that about one-third of the 1.4-year increase in German life expectancy during the period 2001-7 was due to the replacement of older drugs by newer drugs. The effect of the vintage of chemotherapy treatments on age-adjusted cancer mortality rates of residents of France is also investigated, using longitudinal, annual, cancer-site-level data during the period 2002-6. The estimates imply that chemotherapy innovation accounted for at least one-sixth of the decline in French cancer mortality rates, and may have accounted for as much as half of the decline. |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 27% |
| Student > Ph. D. Student | 4 | 18% |
| Professor | 3 | 14% |
| Student > Master | 2 | 9% |
| Other | 1 | 5% |
| Other | 3 | 14% |
| Unknown | 3 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 41% |
| Economics, Econometrics and Finance | 4 | 18% |
| Agricultural and Biological Sciences | 2 | 9% |
| Business, Management and Accounting | 2 | 9% |
| Social Sciences | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 4 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2012.
All research outputs
#4,157,778
of 25,373,627 outputs
Outputs from PharmacoEconomics
#426
of 1,991 outputs
Outputs of similar age
#30,107
of 191,741 outputs
Outputs of similar age from PharmacoEconomics
#113
of 699 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,991 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 191,741 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 699 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.